Biogen Inc. (BIIB) - 5i Research

Biogen Inc. (BIIB $149.89)
- $149.89 P/E (TTM): 14.14X Cap: $22B
- View BIIB Profile
- View Questions on BIIB

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

Amazon.com Inc. (AMZN $224.21)
- $224.21 P/E (TTM): 33.7X Cap: $2.39T
- View AMZN Profile
- View Questions on AMZN
Biogen Inc. (BIIB $149.89)
- $149.89 P/E (TTM): 14.14X Cap: $22B
- View BIIB Profile
- View Questions on BIIB
Intuitive Surgical Inc. (ISRG $546.51)
- $546.51 P/E (TTM): 76.78X Cap: $195.91B
- View ISRG Profile
- View Questions on ISRG
Netflix Inc. (NFLX $1,094.69)
- $1,094.69 P/E (TTM): 47.45X Cap: $465.16B
- View NFLX Profile
- View Questions on NFLX
Edwards Lifesciences Corporation (EW $76.10)
- $76.10 P/E (TTM): 11.01X Cap: $44.67B
- View EW Profile
- View Questions on EW
Celestica Inc. (CLS $415.50)
- $415.50 P/E (TTM): 60.19X Cap: $47.79B
- View CLS Profile
- View Questions on CLS
Global X S&P 500 Index Corporate Class ETF (HXS $97.95)
- $97.95 Cap: $5.30B
- View HXS Profile
- View Questions on HXS
Global X S&P/TSX Capped Energy Index Corporate Class ETF (HXE $39.32)
- $39.32 Cap: $114M
- View HXE Profile
- View Questions on HXE
Berkshire Hathaway Inc. (BRK.B $492.10)
- $492.10 P/E (TTM): 16.86X Cap: $1.05T
- View BRK.B Profile
- View Questions on BRK.B

Q: Greetings - To postpone tax liability from income, I would like to develop a balanced portfolio of stocks and ETFs for the medium term (3-10 years) that do not pay dividends or interest. Rather, I would prefer to incur the tax liability upon selling the holdings (capital gains). I am aware of Global X Total Return ETFs and stocks like BRK.B that do not pay annual dividends. Do you have any other suggestions? Thanks

Read Answer Asked by Alex on July 25, 2025

Amgen Inc. (AMGN $291.76)
- $291.76 P/E (TTM): 23.93X Cap: $157.07B
- View AMGN Profile
- View Questions on AMGN
Biogen Inc. (BIIB $149.89)
- $149.89 P/E (TTM): 14.14X Cap: $22B
- View BIIB Profile
- View Questions on BIIB
Gilead Sciences Inc. (GILD $120.94)
- $120.94 P/E (TTM): 24.0X Cap: $150.06B
- View GILD Profile
- View Questions on GILD
Intuitive Surgical Inc. (ISRG $546.51)
- $546.51 P/E (TTM): 76.78X Cap: $195.91B
- View ISRG Profile
- View Questions on ISRG
AbbVie Inc. (ABBV $227.99)
- $227.99 P/E (TTM): 109.21X Cap: $402.75B
- View ABBV Profile
- View Questions on ABBV
Eli Lilly and Company (LLY $825.45)
- $825.45 P/E (TTM): 53.1X Cap: $777.07B
- View LLY Profile
- View Questions on LLY

Q: Do you have any suggestions re the Pharma companies which would be a good time to purchase now, either in a partial or full position? Thanks

Read Answer Asked by FORREST on March 21, 2025

Biogen Inc. (BIIB $149.89)
- $149.89 P/E (TTM): 14.14X Cap: $22B
- View BIIB Profile
- View Questions on BIIB
Abbott Laboratories (ABT $126.85)
- $126.85 P/E (TTM): 15.85X Cap: $220.77B
- View ABT Profile
- View Questions on ABT
Eli Lilly and Company (LLY $825.45)
- $825.45 P/E (TTM): 53.1X Cap: $777.07B
- View LLY Profile
- View Questions on LLY
Pfizer Inc. (PFE $24.76)
- $24.76 P/E (TTM): 13.12X Cap: $140.77B
- View PFE Profile
- View Questions on PFE
Novo Nordisk A/S (NVO $52.96)
- $52.96 P/E (TTM): 15.16X Cap: $363.68B
- View NVO Profile
- View Questions on NVO

Q: November 2020 was your last response on the business fundamentals of this company. Recognizing that the stock price has dropped even more since then, what has changed with this company's outlook when comparing time periods?

How is its balance sheet and drug pipeline compared to Pfizer?

Pfizer is clearly more of an income play but that aside, do you favour one or the other for any particular reason?

Read Answer Asked by James on February 25, 2025